BIIB

Biogen
Biotechnology · Health Care · as of 2026-11-20
Last close
$250.16
+1.2% on the session
1-year return
+49.0%
+29.1% over six months
Volatility
34.2%
annualized, trailing year
Max drawdown
-14.3%
worst peak to trough, 1y
What the numbers say

Biogen is a biotechnology name in the health care sector. Over the past year it returned +49.0%, against +14.7% over three months and -1.4% over one. It trades 20.9% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 34.2% is above the market's typical range.

Its worst peak-to-trough decline over the year was -14.3%, and it has traded a median $243M a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.16 with the S&P 500 proxy, so it has been moving substantially on its own.

Where it ranks
Within Health Care#6 of 59
Stronger than 91% of its sector on the momentum profile
Across the whole index#9 of 497

How BIIB scores on all four profiles

Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 7 others in Biotechnology.

Start a free 7-day trial
Full metrics
1 day+1.2%
1 week-1.3%
1 month-1.4%
3 months+14.7%
6 months+29.1%
1 year+49.0%
12-1 momentum+51.2%
Volatility (1y, annualized)34.2%
Max drawdown (1y)-14.3%
Distance vs 200-day average+20.9%
Return per unit of risk1.43
Median daily dollar volume$243M
Free newsletter

Get BIIB when it shows up in a ranking

Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.

Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.